Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 317549

Drug Profile

RO 317549

Alternative Names: RO 318161

Latest Information Update: 14 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antihyperlipidaemics; Antirheumatics; Indoles; Maleimides; Small molecules
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Atherosclerosis; Cancer; Coronary artery restenosis; Rheumatic disorders

Most Recent Events

  • 12 Jul 1999 No-Development-Reported for Asthma in Switzerland (Unknown route)
  • 12 Jul 1999 No-Development-Reported for Atherosclerosis in United Kingdom (Unknown route)
  • 12 Jul 1999 No-Development-Reported for Coronary artery restenosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top